A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Inclusion Criteria

• •Inclusion:
• •Unresectable or metastatic pancreas cancer; participants with previous radical surgery for pancreas cancer are eligible after progression is documented
• •Participants may have received previous adjuvant treatment with gemcitabine with or without radiotherapy for pancreas cancer
• •ECOG (Eastern Cooperative Oncology Group) Performance status ≤ 2
• •Adequate organ function
• •Have an estimated life expectancy of at least 12 weeks and in the judgment of the investigator, will be able to complete at least 2 cycles of treatment
• •Ability to perform the indicated functional performance measures at baseline
• •Exclusion:
• •Prior systemic therapy for unresectable/metastatic pancreas cancer
• •Any medical or psychiatric condition, orthopedic or neuromuscular conditions that could limit participation or confound study results
• •Currently taking medications that are considered both muscle building and performance enhancing (for example, androgen therapies, or anabolic steroids)